Circulating MiRNA 27a and MiRNA150-5p; a Noninvasive Approach to Endometrial Carcinoma
Overview
Affiliations
The search for novel non-invasive biomarkers such as epigenetic molecular markers is new hope for common and burdensome cancers. We aim to assess serum expression of miRNA 27a and miRNA150-5p in endometrial cancer patients. Serum was drawn for 36 un-intervened endometrial cancer patients scheduled for hysterectomy and 35 controls. miRNA 27a and miRNA150-5p were measured by real time reverse transcription polymerase chain reaction. Significant overexpression of both miRNA in patients (p < 0.001). At cutoffs 0.2872 & > 1.02, miRNA 27a showed 100% sensitivity, specificity, positive and negative predictive values. miRNA150-5p showed 88.89% sensitivity, 100% specificity, 100% positive and 78.9% negative predictive values. Areas under curve were 1.0 for miRNA 27a, 0.982 for miRNA 150 performing much better than Ca125. miRNA 27a was significantly associated with type I endometroid endometrial cancer. Conclusion: miRNA 27a and miRNA-150-5P can be suggested as promising biomarkers of endometrial cancer possibly part of a miRNA panel for management.
Ghaderi P, Fallah S, Khaledi H, Tehranian A, Rahmati F, Sheikhhasani S Acta Endocrinol (Buchar). 2023; 19(1):1-9.
PMID: 37601705 PMC: 10439323. DOI: 10.4183/aeb.2023.1.
The Role of miRNAs in the Development, Proliferation, and Progression of Endometrial Cancer.
Bogaczyk A, Zawlik I, Zuzak T, Kluz M, Potocka N, Kluz T Int J Mol Sci. 2023; 24(14).
PMID: 37511248 PMC: 10380838. DOI: 10.3390/ijms241411489.
Piergentili R, Gullo G, Basile G, Gulia C, Porrello A, Cucinella G Int J Mol Sci. 2023; 24(14).
PMID: 37511115 PMC: 10379073. DOI: 10.3390/ijms241411356.
Thakur L, Thakur S Front Endocrinol (Lausanne). 2023; 14:1166948.
PMID: 37152960 PMC: 10161733. DOI: 10.3389/fendo.2023.1166948.
Karkia R, Wali S, Payne A, Karteris E, Chatterjee J Cancers (Basel). 2022; 14(19).
PMID: 36230588 PMC: 9563808. DOI: 10.3390/cancers14194666.